'Radical rethink needed to tackle hunger, obesity'

Agencies
January 29, 2019

Paris, Jan 29: To defeat the intertwined pandemics of obesity, hunger and climate change, governments must curb the political influence of major corporations, said a major report Monday calling for a 'global treaty' similar to one for tobacco control.

But this will not happen unless ordinary citizens demand a "radical rethink" of the relationship between policymakers and business, nearly four dozen experts from The Lancet Commission on Obesity concluded.

"Powerful opposition from vested interests, lack of political leadership, and insufficient societal demand for change are preventing action," they said in a statement.

Nearly a billion people are hungry and another two billion are eating too much of the wrong foods, causing epidemics of obesity, heart disease and diabetes.

Unhealthy diets account for up to 11 million premature deaths every year, according to the most recent Global Disease Burden report.

"Malnutrition in all its forms -- including undernutrition and obesity -- is by far the biggest cause of ill-health and premature death globally," said Commission co-chair Boyd Swinburn, a professor at the University of Aukland.

"Both undernutrition and obesity are expected to be made significantly worse by climate change."

The way in which food is currently produced, distributed and consumed not only fuels the hunger and obesity pandemics, it also generates 25 to 30 percent of planet-warming greenhouse gas emissions.

Cattle production alone accounts for more than half of those gases, in the form of methane-laden flatulence and CO2 when forests -- especially in Brazil -- are cleared to make room for livestock.

A transport system dominated by cars contributes another 15 to 25 percent of emissions, and supports a sedentary lifestyle.

 "Underpinning all of these are weak political governance, the unchallenging economic pursuit of GPD growth, and the powerful commercial engineering of overconsumption," the report said.

"Undernutrition is declining too slowly to meet global targets, no country has reversed its obesity epidemic, and comprehensive policy responses to the threat of climate change have barely begun."

Despite 30 years of warnings from science about the dire impacts of global warming, CO2 emissions hit record levels in 2017 and again last year.

Because all these problems are interwoven, the answers must be too, the researchers emphasised.

"Joining three pandemics" -- hunger, obesity, climate -- "together as 'The Global Syndemic' allows us to consider common drivers and shared solutions."

Another Lancet Commission report published last week calling for a dramatic shift in global diet to improve health and avoid "catastrophic" damage to the planet.

"Until now, undernutrition and obesity have been seen as polar opposites of either too few or too many calories," said Swinburn.

"In reality, they are both driven by the same unhealthy, inequitable food systems, underpinned by the same political economy."

The report calls for a Framework Convention on Food Systems -- similar to global conventions for tobacco control and climate change -- to restrict the influence of the food industry.

The experts argue that economic incentives must be overhauled.

Some five trillion dollars (4.4 trillion euros) in government subsidies for fossil fuels and large-scale agribusiness should be rechanneled toward "sustainable, healthy and environmentally friendly activities," they said.

To sharply reduce red meat consumption, for example, the report favours high taxes, abolishing subsidies, along with transparent health and environment labelling.

In addition, they favour the creation of a one billion dollar philanthropic fund to support grassroots action.

"Support from civil society is crucial to break the policy deadlock," said co-author William Dietz, a professor at George Washington University.

"As with other social movements -- such as campaigns to introduce sugary drink taxes -- efforts ... are more likely to begin at the community, city or state level."

Nearly all facets of daily life are at play.

"Tackling 'The Global Syndemic' requires an urgent rethink of how we eat, live, consume and move," said Richard Horton, editor-in-chief of The Lancet.

The two Lancet reports are not the only urgent appeal from science in recent months. In October, the UN's Intergovernmental Panel on Climate Change likewise called for an economic and social "paradigm shift" to avoid global chaos.

Health advocates and climate experts hailed The Lancet commission's sweeping call for deep change.

"For too long we have been day-dreaming our way to a diseased future," said Katie Dain, CEO of the Noncommunicable Disease Alliance.

"A food system that secures a better diet for this and the immediate next generations will save millions of lives and, at the same time, help save the planet."

Industry representatives and libertarians slammed the findings as overwrought and an assault on free choice.

"Nanny-state zealots are no longer hiding their intention to use the anti-tobacco blueprint to control other areas of our lives," said Christopher Snowdon, head of lifestyle economics at the London-based Institute of Economic Affairs.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 24,2020

Colorado, Jul 24: A new study has found that physical stress in one's job may be associated with faster brain ageing and poorer memory.

Aga Burzynska, an assistant professor in the Department of Human Development and Family Studies, and her research team connected occupational survey responses with brain-imaging data from 99 cognitively normal older adults, age 60 to 79. They found that those who reported high levels of physical stress in their most recent job had smaller volumes in the hippocampus and performed poorer on memory tasks. The hippocampus is the part of the brain that is critical for memory and is affected in both normal ageing and in dementia.

Their findings were published this summer in Frontiers in Human Neuroscience under the research topic 'Work and Brain Health Across the Lifespan.'

"We know that stress can accelerate physical ageing and is the risk factor for many chronic illnesses," Burzynska said. "But this is the first evidence that occupational stress can accelerate brain and cognitive ageing."

She added that it is important to understand how occupational exposures affect the ageing of our brains.

"An average American worker spends more than eight hours at work per weekday, and most people remain in the workforce for over 40 years," Burzynska said. "By pure volume, occupational exposures outweigh the time we spend on leisure social, cognitive and physical activities, which protect our ageing minds and brains."

Physical demands at work

Burzynska explained that the association between "physical stress" and brain/memory were driven by physical demands at work. These included excessive reaching, or lifting boxes onto shelves, not necessarily aerobic activity. This is important because earlier work by Burzynska and her colleagues showed that leisure aerobic exercise is beneficial for brain health and cognition, from children to very old adults. Therefore, the researchers controlled for the effects of leisure physical activity and exercise.

As expected, leisure physical activity was associated with greater hippocampal volume, but the negative association with physical demands at work persisted.

"This finding suggests that physical demands at work may have parallel yet opposing associations with brain health," Burzynska explained. "Most interventions for postponing cognitive decline focus on leisure, not on your job. It's kind of unknown territory, but maybe future research can help us make some tweaks to our work environment for long-term cognitive health."

She added that the results could have important implications for society.

"Caring for people with cognitive impairment is so costly, on economic, emotional and societal levels," Burzynska said. "If we can support brain health earlier, in middle-aged workers, it could have an enormous impact."

The researchers considered and corrected for several other factors that could be related to work environment, memory and hippocampus, such as age, gender, brain size, educational level, job title, years in the occupation and general psychological stress.

One piece of the puzzle

"The research on this topic is so fragmented," Burzynska said. "One previous study linked mid-life managerial experience with greater hippocampus volume in older age. Another showed that taxi drivers had larger hippocampi than a city's bus drivers, presumably due to the need to navigate. In our study, job complexity and psychological stress at work were not related to hippocampal volume and cognition. Clearly, our study is just one piece of the puzzle, and further research is needed."

The magnetic resonance imaging (MRI) data used for the study was collected at the University of Illinois Urbana-Champaign between 2011 and 2014.

CSU researchers now can collect MRI data with the new 3T scanner at the University's Translational Medicine Institute.

With this new capability, Burzynska, along with Michael Thomas and Lorann Stallones of CSU's Department of Psychology, is launching a new project, "Impact of Occupational Exposures and Hazards on Brain and Cognitive Health Among Aging Agricultural Workers," which will involve collecting MRI brain scans and identifying risk and protective factors that could help the agricultural community age successfully. The project recently obtained funding as an Emerging Issues Short-Term Project from the High Plains Intermountain Center for Agricultural Health and Safety.

The Department of Human Development and Family Studies is part of CSU's College of Health and Human Sciences.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 10,2020

Early treatment with the antiviral drug remdesivir has been found to reduce viral load and prevent lung disease in macaques infected with SARS-CoV-2 that causes COVID-19, according to a study.

The findings, published in the journal Nature on Tuesday, support the early use of remdesivir treatment in patients with COVID-19 to prevent progression to pneumonia.

Researchers from the National Institutes of Health in the US noted that remdesivir has broad antiviral activity and has been shown to be effective against infections with SARS-CoV and MERS-CoV in animal models.

The drug is being tested in human clinical trials for the treatment of COVID-19, they said.

Researcher Emmie de Wit and colleagues investigated the effects of remdesivir treatment in rhesus macaques, a recently established model of SARS-CoV-2 infection.

Two sets of six macaques were inoculated with SARS-CoV-2.

One group was treated with remdesivir 12 hours later -- close to the peak of virus reproduction in the lungs -- and these macaques received treatment every 24 hours until six days after inoculation.

In contrast to the control group, the researchers found that macaques that received remdesivir did not show signs of respiratory disease, and had reduced damage to the lungs.

Viral loads in the lower respiratory tract were also reduced in the treated animals; viral levels were around 100 times lower in the lower-respiratory tract of remdesivir-treated macaques 12 hours after the first dose, they said.

The researchers said that infectious virus could no longer be detected in the treatment group three days after initial infection, but was still detectable in four out of six control animals.

Despite this virus reduction in the lower respiratory tract, no reduction in virus shedding was observed, which indicates that clinical improvement may not equate to a lack of infectiousness, they said.

Dosing of remdesivir in the rhesus macaques is equivalent to that used in humans, the researchers noted.

They cautioned that it is difficult to directly translate the timing of treatment used in corresponding disease stages in humans, because rhesus macaques normally develop only mild disease.

However, researchers said the results indicate that remdesivir treatment of COVID-19 should be initiated as early as possible to achieve the maximum treatment effect.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 4,2020

The World Health Organisation on Wednesday said that anti-malarial drug hydroxychloroquine (HCQ) will return to the solidarity trial for the potential treatment of coronavirus disease.

At a press conference in the WHO headquarters in Geneva, Director General Tedros Adhanom Ghebreyesus said: "On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol. The Executive Group received this recommendation and endorsed continuation of all arms of the solidarity trial, including hydroxychloroquine."

The world health body had temporarily suspended the usage of HCQ from the solidarity trial for coronavirus treatment on May 25 soon after a study published in one of the most reliable medical journals, which had suggested that the drug could cause more fatalities among COVID-19 patients.

However, the WHO chief said that the decision was taken as a precaution while the safety data was reviewed.

Ghebreyesus also said that the Data Safety and Monitoring Committee will continue to closely monitor the safety of all therapeutics being tested in the solidarity trial.

"So far, more than 3,500 patients have been recruited in 35 countries. WHO is committed to accelerating the development of effective therapeutics, vaccines and diagnostics as part of our commitment to serving the world with science, solutions and solidarity," he said.

Soon after HCQ was suspended from the trial, the Indian government had said that the antimalarial drug has been known for its benefits for a long time and its usage will be continued on the frontline workers, including police and healthcare professionals, as prophylaxis. The government had also said that studies were being conducted and the drug would be included in the clinical trial also for the treatment of coronavirus disease.

US President Donald Trump also had strongly advocated the use of HCQ and called it a "game-changer". He went to the extent of saying that he had taken the medicine.

Launched by WHO and partners, solidarity trial is an international clinical trial to find an effective treatment for COVID-19, including drugs to slow the progression of the disease or improve survival. The trial, which enrols patients from different countries, "will compare four treatment options against standard of care to assess their relative effectiveness against COVID-19", said WHO. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.